top of page


  1. Guadagnolo BA, Liao KP, Elting L, Giodano S, Buchholz and Shih YCT.  Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States.  J Clin Oncol 2012; 31:80-87.

  2. Park KR, Lee CG, Tseng YD, Liao JL, Reddy S, Bruera E, Yennurajalingam S.  Palliative radiation therapy in the last 30 days of life: A systematic review.  Radioth and Oncol 2017, 125:193:199.

  3. Harris AA, Hartsell WF.  Palliation of Bone mestastases.  En Principles and practice of radiation oncologist, seventh edition.  Perez and Brady´s, 2019:6742-6785

  4. Shiloh R, Krishnan M.  Radiation for treatment of painful Bone metastases.  Hematol Oncol Clin N Am 2018; 32:459-468. 

  5. Van der Velden JM, van der Linden YM, Versteeg AL et al.  Evaluation of effectiveness of palliative radiotherapy for bone metastases: a prospective cohort study.  J Radiat Oncol 2018; 7:325-333.

  6. Tong D, Gillick L, Hendrickson FR.  The palliation of symptomatic osseous metastases: final results of the study by de radiation therapy oncology group.  Cancer 1982; 50:893-899.

  7. Bone Pain Trial Working Party.  8 Gy single fraction radiotherapy for the treatment of metastasic skeletal pain: randomized comparison with a multifraction schedule over 12 months of pacients follow-up.  Radiother Oncol 1999; 52(2):111-121

  8. Hartsell WF, Scott CB, Bruner DW et al.  Randomized trial of short versus long-course radiotherapy for palliation of painful bone metastases.  J Natl Cancer Inst 2005; 97:798-804.

  9. McDonald R, Chow E, Lam H, Rowbottom L, Soliman H.  International patterns of practice in radiotherapy for bone metastases: a review of the literatura.  J Bone Oncol 2014; 3:96-102.

  10. Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S.  Update on the systematic review of palliative radiotherapy trials for bone metaswtses.  Clin Oncol (R Coll Radio) 2012; 24:112-124.

  11. Suzuki G, Yamazaki H, Aibe N et al.  Paliative reirradiation for painful b one metastases: clinical cases and literatura review.  Kurume medical Journal 2017; 64(1):2-11.

  12. Wong E, Hoskin P, Bedard G et al.  Reirradiation for painful bone metastases – a systematic review.  Radiother Oncol 2014; 110:61-70.



  1. Drouin L, Pistorius MA, Lafforgue A, N’Gohou C, Richard A, Connault J, Espitia O. Upper-extremity venous thrombosis: A retrospective study about 160 cases. Rev Med Interne. 2018 Aug 16; [PubMed: 30122260].

  2. Zimmerman S, Davis M. Rapid Fire: Superior Vena Cava Syndrome. Emerg. Med. Clin. North Am. 2018 Aug; 36(3):577-84. [PubMed: 30037444].

  3. Carmo J, Santos A. Chronic Occlusion of the Superior Vena Cava. N. Engl. J. Med. 2018 Jul 05; 379(1):e2. [PubMed: 29972752].

  4. Seligson MT, Surowiec SM. Superior vena cava syndrome. NCBI Bookshelf October 2018.

  5. Cheng S. Superior vena cava syndrome: A contemporary review of a historic disease. Cardiol Rev 2009; 17:16-23.

  6. Ostler PJ, Clarke DP, Watkinson AF, Gaze MN. Superior vena cava obstruction: A modern management strategy. Clin Oncol (R Coll Radiol) 1997; 9:83-9.

  7. Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: Clinical characteristics and evolving etiology. Medicine (Baltimore) 2006; 85:37-42.

  8. Yellin A, Rosen A, Reichert N, Lieberman Y. Superior vena cava syndrome. The myth-The facts. Am Rev Respir Dis 1990; 141(5 Pt1):1114-8.

  9. Lochridge SK, Knibbe WP, Doty DB. Onstruction of the superior vena cava. Surgery 1979; 85:14-24.

  10. Nogeire C, Mincer F, Botstein C. Long survival in patients with bronchogenic carcinoma complicated by superior vena caval obstruction. Chest 1979; 75:325-9.

  11. Ahmann FR. A reassessment of the clinical implications of the superior vena caval syndrome. J Clin Oncol 1984; 2:961-9.

  12. Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus. Cochrane Database Syst Rev 2001.

  13. Perez-Soler R, McLaughlin P, Velasquez WS, Hagemeister FB, Zornoza J, Manning JT, et al. Clinical features and results of management of superior vena cava syndrome secondary to lymphoma. J Clin Oncol 1984; 2:260-6;

  14. Gucalp R, Dutcher J. Oncologic emergencies. In: Fauci AS, Braunwld E, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s Principles of Internal Medicine. 19th ed.

  15. De Potter B, Huyskens J, Hiddinga B, Spinhoven M, Janssens A, van Meerbeeck JP, Parizel PM, Snoeckx A. Imaging of urgencies and emergencies in the lung cancer patient. Insights Imaging. 2018 Aug; 9(4):463-76. [PMC free article: PMC6108967] [PubMed: 29644546].

  16. Friedman T, Quencer KB, Kishore SA, Winokur RS, Madoff DC. Malignant Venous Obstruction: Superior vena cava syndrome and Beyond. Semin Intervent Radiol. 2017 Dec; 34(4):398-408. [PMC free article: PMC5730434] [PubMed: 29249864].

  17. Goodman R. Superior vena cava syndrome. Clinical management. JAMA 1975; 231:58-61.

  18. Wan JF, Bezjak A. Superior vena cava síndrome. Emerg Med Clin North Am 2009; 27:243-55.

  19. Straka C, Ying J, Kong FM, Willey CD, Kaminski J, Kim DW. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome. SpringerPlus 2016; 5: 229.

  20. Lonardi F, Gioga G, Agus G, Coeli M, Campostrini F. Double-flash, large-fraction radiation therapy as palliative treatment of malignant superior vena cava síndrome in the elderly. Support Care Cancer 2002; 10(2): 156-60.

  21. Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome-a proposed classification system and algorithm for management. J Thorac Oncol 2008; 3(8): 811-4.

  22. Kishi K, Sonomura T, Mitsuzane K, Nishida N, Yang RJ, Sato M, et al. Self-expandable metallic stent therapy for superior vena cava syndrome: clinical observations. Radiology 1993; 189(2): 531-5.

  23. Mansour A, Saadeh SS, Abdel-Razeq N, Khozouz O, Abunasser M, Taqash A. Clinical Course and Complications of Catheter and Non-Catheter-Related Upper Extremity Deep Vein Thrombosis in Patients with Cancer. Clin. Appl. Thromb. Hemost. 2018 Nov; 24(8):1234-40. [PubMed: 30025472].

  24. Khan UA, Schanholtz CB, McCurdy MT. Oncologic Mechanical Emergencies. Hematol. Oncol. Clin. North Am. 2017 Dec; 31(6):927-40. [PubMed: 29078930].

  25. Chan RH, Dar AR, Yu E, Stitt LW, Whiston F, Truong P, et al. Superior vena cava obstruction in small-cell lung cancer. Int J Radiat Oncol Biol Phys 1997; 38:513-20.

  26. Gauden SJ. Superior vena cava syndrome induced by bronchogenic carcinoma: Is this an oncological emergency? Australas Radiol 1993; 37:363-6.

  27. Schraufnagel DE, Hill R, Leech JA, Pare JAP. Superior vena caval obstruction: is it a medical emergency? Am J Med 1981; 70(6): 1169-74.

  28. Ampil F, Caldito G, Previgliano C. Palliative radiotherapy for superior vena caval obstruction by lung cancer: A major issue about timing and a minor issue about efficacy. Ann Thorac Med 2012; 7:170-1.

  29. Davenport D, Ferree C, Blake D, Raben M. radiation therapy in the treatment of superior vena caval obstruction. Cancer 1978; 42(6): 2600-3.

  30. Watkinson AF, Yeow TN, Fraser C. Endovascular stenting to treat obstruction of the superior vena cava. BMJ 2008; 336(7658): 1434-7.

  31. Armstrong BA, Perez CA, Simpson JR, Hederman MA. Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys 1987; 13(4): 531-9.

  32. Lepper PM, Ott SR, Hoppe H, Schumann C, Stammberger U, Bugalho A, et al. Superior vena cava syndrome in thoracic malignancies. Respir Care 2011; 56(5): 653-66.

  33. Magnan PE, Thomas P, Guidicelli R, Fuentes P, Brancherau A. Surgical reconstruction of the superior vena cava. Cardiovasc Surg 1994; 2(5): 598-604.



  1. Monti M, Castellani L, Berlusconi A, et al. Use of red blood cell transfusions in terminally ill cáncer patients admitted to a palliative care unit. J Pain Symptom Manage 1996;12:18-22.

  2. Pereira J, Phan T: Management of bleeding in patients with advanced cáncer. Oncologist  2004, 9: 561-570.

  3. Johnstone C, Rich S. Bleeding in cancer patients and its treatment: a review Ann Palliat Med 2018;7(2):265-273.

  4. Verheij M, Dewit LG, Boogaard MN, Brinkman HJ, Van Mourik JA: Ionizing radiation enhances platelet adhesion to the extracellular matrix of human endothelial cells by an increase in the release of von Villebrand factor. Radiat Res 1994, 137: 202-207.

  5. Yarnold J, Brotons MC. Pathogenetic mechanism in radiation fibrosis. Radiother Oncol 2010, 97: 149-161.

  6. Sapienza L Ning M Jhingran A Lin L Leão C.  Clinical and Translational Radiation Oncology. 2019 vol: 14 pp: 40-46.

  7. Asakura H, Hashimoto T, Hideyuki H.  Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate?.J Cancer Res Clin Oncol (2011) 137:125–130.

  8. Cameron M, Kersten C, Vistad I, Guren S.  Palliative pelvic radiotherapy of symptomatic incurable rectal cancer – a systematic review, Acta Oncologica (2014), 53:2, 164-173.

  9. Cameron M, Kersten C, Vistad I, Guren S. Palliative pelvic radiotherapy of symptomatic incurable prostate cancer – A systematic review. Radiotherapy and Oncology (2014). Volume 110, Issue 1, Pages 55-60.

  10.  Kramer GWPM, Gans S, Ullmann E, et al. Hypofractionated external beam radiotherapy as retreatment for symptomatic non-small-cell lung carcinoma: an effective treatment? Int J Radiat Oncol Biol Phys 2004;58(5):1388–93.

  11. Cross C, Berman S, Buswell L. Prospectiva Study of palliative hipofractionated Radiotherapy (8.5Gy x2) for patients with symptomatic NSCLC. Int. J. Radiation Oncology Biol. Phys. 2004, Vol. 58, No. 4, pp. 1098–1105,

  12. Kim D, Lee J, Ki Y, Nam J, Kim W et. al. Short-course palliative radiotherapy for uterine cervical cáncer. Radiation Oncology Journal 2013 vol: 31 (4) pp: 216.

  13. Eleje GU, Eke AC, Igberase GO, Igwegbe AO, Eleje LI. Palliative interventions for controlling vaginal bleeding in advanced cervical cancer. Cochrane Database of Systematic Reviews 2015, Issue 5.

  14. Senkus-Konefka E, Dziadziuszko R, Bednaruk-Młyński E, Pliszka A, Kubrak J et. al British Journal of Cancer. A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC).. 2005 vol: 92 (6) pp: 1038-1045.

  15. Tey J, Choo BA, Leong CN, et al. Clinical outcome of palliative radiotherapy for locally advanced symptomatic gastric cancer in the modern era. Medicine 2014;93(22):e118.

  16. Tey, Jeremy et al. “Palliative radiotherapy for gastric cancer: a systematic review and meta analysis” Oncotarget vol. 8,15 (2017): 25797-25805.

  17. Cross C, Berman S, Buswell L, Johnson B, Baldini E. Prospective study of palliative hypofractionated radiotherapy (8.5 Gy × 2) for patients with symptomatic non–small-cell lung cáncer. International Journal of Radiation Oncology*Biology*Physics 2004 vol: 58 (4) pp: 1098-1105.

  18. Kawabata H Uno K Yasuda K Yamashita M. Experience of Low-Dose, Short-Course Palliative Radiotherapy for Bleeding from Unresectable Gastric Cancer. Journal of Palliative Medicine 2017 vol: 20 (2) pp: 177-180.

  19. Lee YH, LEE JW, Jang HS. Palliative external beam radiotherapy for the treatment of tumor bleeding in inoperable advanced gastric cáncer. BMC cancer 2017; 17: 17: 254.

  20. Cihoric N, Crowe S, Eychmüller S, Aebersold DM, Ghadjar P: Clinically significant bleeding in incurable cancer patients: effectiveness of hemostatic radiotherapy. Radiat Oncol. 2012, 7:132.

  21. Senkus-Konefka E, Dziadziuszko R, Bednaruk-Młyński E, et al. A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC). Br J Cancer. 2005;92(6):1038-45.

  22. Medical Research Council Lung Cancer Working Party (1991) Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer 63: 265–270.

  23. Rodrigues G, Videtic G, Sur R, Bezjak A, Bradley J, et. al. Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline. Practical radiation oncology 2011 vol: 1 (2) pp: 60-71.



  1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995; 13: 8–10.

  2. Milano MT, Katz AW, Muhs AG, Philip A, Buchholz DJ, Schell MC, et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cáncer 1 de febrero de 2008;112(3):650-8.

  3. Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010;40(2):107- 111.

  4. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997; 15: 938–946.

  5. Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013;14:e28-e37.

  6. Aboulafia AJ, Levine AM, Schmidt D, Aboulafia D. Surgical therapy of bone metastases. Semin Oncol. 2007;34:206–214. 8.

  7. Kanner AA, Bokstein F, Blumenthal DT, Ram Z. Surgical therapies in brain metastasis. Semin Oncol. 2007;34:197–205. 9.

  8. Kuvshinoff B, Fong Y. Surgical therapy of liver metastases. Semin Oncol. 2007;34:177–185. 10.

  9. Sternberg DI, Sonett JR. Surgical therapy of lung metastases. Semin Oncol. 2007;34:186–196

  10. Dhakal S, Corbin KS, Milano MT, et al. Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival.

  11. Stinauer MA, Kavanagh BD, Schefter TE, et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011;6:34

  12. Ranck MC, Golden DW, Corbin KS, et al. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol. 2013;36(6):589-595.

  13. Fuks Z, Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell. 2005;8(2):89-91

  14. Hong JC, Salama JK. The expanding role of stereotactic body radiation therapy in oligometastatic solid tumors: What do we know and where are we going? Cancer Treatment Reviews. enero de 2017;52:22-32

  15. Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with nonsmall-cell lung cancer. J Clin Oncol. 2011;29(12):1556-1563.

  16. Wong AC, Watson SP, Pitroda SP, et al. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016;122(14):2242- 2250.

  17. Singh D, Yi WS, Brasacchio RA, et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys. 2004;58(1):3-10.

  18.  Dorn PL, Meriwether A, LeMieux M, et al. Patterns of distant failure and progression in breast cancer: implications for the treatment of oligometastatic disease. Int J Radiat Oncol Biol Phys. 2011;81(2 suppl):S643.

  19. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342

  20. Salama JK, Milano MT. Radical irradiation of extracranial oligometastases. J Clin Oncol. 2014;32(26):2902-2912.

  21. Milano MT, Katz AW, Okunieff P. Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ . Am J Clin Oncol . 2010 ; 33 : 157 - 163 .

  22. Timmerman R , McGarry R , Yiannoutsos C , et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer . J Clin Oncol . 2006 ; 24 : 4833 - 4839 .

  23. Park J, Chen YJ, Lu WP, et al. The evolution of liver-directed treatments for hepatic colorectal metastases. Oncology (Williston Park). 2014;28(11):991-1003. PubMed PMID: 25403632.

  24. Chance WW , Nguyen QN , Mehran R , et al. Stereotactic ablative radiotherapy for adrenal gland metastases: factors infl uencing outcomes, patterns of failure, and dosimetric thresholds for toxicity . Pract Radiat Oncol . 2017 ; 7 ( 3 ):e195 - e203 .

  25. Detti B , Bonomo P , Masi L , et al. Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer . World J Urol . 2015 ; 33 : 1197 - 1203 .



  1. Robson P. Metastatic spinal cord compression: a rare but important complication of cancer. Clin Med. 2014;14(5):542-5.

  2. Schiff D, O'Neill BP, Suman VJ. Spinal epidural metastasis as the initial manifestation of malignancy: clinical features and diagnostic approach. Neurology 1997; 49:452.

  3. Baehring JM. Spinal Cord Compression. In: DeVita Jr, Lawrence TS, Rosenberg SA, editors. Cancer. Principles and Practice of Oncology. Philadelphia, Pa: Lippincott Williams & Wilkins; 2008. p. 2441-5.

  4. Cole JS, Patchell RA. Metastatic epidural spinal cord compression. Lancet Neurol 2008; 7:459.

  5. Siegal T. Spinal cord compression: from laboratory to clinic. Eur J Cancer 1995; 31A:1748

  6. Bilsky MH, Laufer I, Fourney DR, et al. Reliability analysis of the epidural spinal cord compression scale. J Neurosurg Spine 2010; 13:324.

  7. Bilsky MH, Laufer I, Fourney DR, et al. Reliability analysis of the epidural spinal cord compression scale. J Neurosurg Spine 2010; 13:324.

  8. Helweg-Larsen S, Hansen SW, Sørensen PS. Second occurrence of symptomatic metastatic spinal cord compression and findings of multiple spinal epidural metastases. Int J Radiat Oncol Biol Phys 1995; 33:595.

  9. Fisher CG, DiPaola CP, Ryken TC, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine (Phila Pa 1976) 2010; 35:E1221.

  10. Sørensen S, Helweg-Larsen S, Mouridsen H, Hansen HH. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer 1994; 30A:22.

  11. Laufer I, Zuckerman SL, Bird JE, et al. Predicting Neurologic Recovery after Surgery in Patients with Deficits Secondary to MESCC: Systematic Review. Spine (Phila Pa 1976) 2016; 41 Suppl 20:S224.

  12. Rades D et al. Validation of a score predicting post-treatment ambulatory status after radiotherapy for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys 2011;79(5):1503–6.

  13. Donovan, E. K., Sienna, J., Mitera, G., Kumar-Tyagi, N., Parpia, S., & Swaminath, A. (2019). Single versus multifraction radiotherapy for spinal cord compression: A systematic review and meta-analysis. Radiotherapy and Oncology, 134, 55–66. doi:10.1016/j.radonc.2019.01.019.

bottom of page